Data gathered: October 4
Alternative Data for MoonLake Immunotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 72 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7,266 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,899 | Sign up | Sign up | Sign up |
| Twitter Followers | 249 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 65 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 140 | Sign up | Sign up | Sign up |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
| Price | $8.43 |
| Target Price | Sign up |
| Volume | 15,400,000 |
| Market Cap | $474M |
| Year Range | $6.25 - $61.99 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost MoneyOctober 4 - GlobeNewswire |
|
 |
MoonLake Immunotherapeutics (NASDAQ:MLTX) Downgraded to “Neutral” Rating by HC WainwrightOctober 3 - ETF Daily News |
|
Research Analysts Set Expectations for MLTX Q1 EarningsOctober 3 - ETF Daily News |
|
Leerink Partnrs Has Negative Estimate for MLTX Q3 EarningsOctober 3 - ETF Daily News |
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 3 - GlobeNewswire |
|
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens BermanOctober 3 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 740,000 | -740,000 | -55M | -53M | -0.870 |
| Q1 '25 | 0 | 380,000 | -380,000 | -40M | -40M | -0.630 |
| Q4 '24 | 100,000 | 51,000 | 51,000 | -46M | -45M | -0.720 |
| Q3 '24 | 0 | 33,000 | -33,000 | -35M | -43M | -0.560 |
| Q2 '24 | 0 | 28,000 | -28,000 | -24M | -31M | -0.390 |
Insider Transactions View All
| Cormorant Asset Management, LP filed to sell 1,994,173 shares at $7. October 1 '25 |
| Cormorant Asset Management, LP filed to sell 8,423,403 shares at $9.4. October 1 '25 |
| Cormorant Asset Management, LP filed to sell 8,190,943 shares at $8.4. October 1 '25 |
| Cormorant Asset Management, LP filed to sell 2,000,000 shares at $6.6. October 1 '25 |
| Cormorant Asset Management, LP filed to sell 4,800,000 shares at $7.6. October 1 '25 |
Similar companies
Read more about MoonLake Immunotherapeutics (MLTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of MoonLake Immunotherapeutics?
The Market Cap of MoonLake Immunotherapeutics is $474M.
What is the current stock price of MoonLake Immunotherapeutics?
Currently, the price of one share of MoonLake Immunotherapeutics stock is $8.43.
How can I analyze the MLTX stock price chart for investment decisions?
The MLTX stock price chart above provides a comprehensive visual representation of MoonLake Immunotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling MoonLake Immunotherapeutics shares. Our platform offers an up-to-date MLTX stock price chart, along with technical data analysis and alternative data insights.
Does MLTX offer dividends to its shareholders?
As of our latest update, MoonLake Immunotherapeutics (MLTX) does not offer dividends to its shareholders. Investors interested in MoonLake Immunotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of MoonLake Immunotherapeutics?
Some of the similar stocks of MoonLake Immunotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.